CpG ODN (K3)—toll-like receptor 9 agonist—induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study

by Hamaguchi, M., Hirata, H., Ishii, K.J, Kida, H., Kimura, K., Kumanogoh, A., Kuroda, E., Manabe, Y., Miyake, K., Mizuno, Y., Nishida, S., Otsuka, T., Shibahara, T., Shiroyama, T., Takeda, Y., Temizoz, B., Yagita, M.
Published 2022

Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in Decedents Undergoing Forensic Postmortem Examination: Feasibility for Real-Time Pandemic Surveillance

by Althoff, K.N, Baker, O.R, Coburn, S.B, Dennis Thomas, F., Ehsani, J., Graham, L.A, Klock, E., Laeyendecker, O., Li, L., Li, R., Manabe, Y.C, Michael, J.P, Quinn, T.C, Sherman, S.G, Shields, W.C, Southall, P., Weedn, V.W
Published 2022